Consensus on Middle Meningeal Artery Embolization for Chronic SubDural Hematoma
Author Information
Author(s): Bartek J., Biondi A., Bonhomme V., Castellan L., Catapano G., Cenzato M., Di Nuzzo G., De Robertis E., Giordano F., Iaccarino C., Kulcsar Z., Möhlenbruch M.A., Raabe A., Rickard F., Romero C.S., Schubert T., Shipway D., Sicignano C., Muto M.
Primary Institution: Karolinska University Hospital, Stockholm, Sweden
Hypothesis
What is the current role of middle meningeal artery embolization (MMAE) in the treatment of chronic subdural hematoma (cSDH)?
Conclusion
The panel reached a consensus that MMAE should be considered as a treatment option for both de novo and recurrent cSDH, especially in patients at high risk for surgery.
Supporting Evidence
- MMAE has shown promising results in observational datasets.
- Consensus reached on MMAE's role in de novo and recurrent cSDH.
- MMAE is recommended for patients on antithrombotics or with coagulopathy.
- Current practice varies widely across different centers regarding MMAE.
Takeaway
Doctors agree that a new treatment called MMAE can help patients with chronic subdural hematomas, especially if they can't have surgery.
Methodology
A literature search was performed to gather existing data on MMAE and cSDH, followed by a round-table discussion among experts to reach a consensus.
Potential Biases
There is a risk of selection bias in observational datasets and subjective assessment by treatment physicians.
Limitations
The consensus statement does not follow a Delphi process and lacks randomized controlled trial data to support its recommendations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website